Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Axsome Thera

(NASDAQ: AXSM)
Add to Portfolio
-3.68 (-6.87%)
as of Apr 7, 2020

Last 49.87
Change -3.68 (-6.87%)
Open 54.31
Prev. Close 53.55
Today's Range
49.36
54.76
52wk Range
13.25
109.94
Volume 1362326
Avg Volume 1263410
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
AXSM -6.87% -42.66% +243.93%
DJIA -0.12% -20.61% -14.27%
S&P 500 -0.16% -18.01% -8.07%

Key Statistics

Annual EPS -2.00
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 2039890
Weighted Alpha +66.50
Standard Deviation -0.65
Profit Margin N/A
Beta 3.11

Growth Rates

YTD -51.75%
1-Year +297.85%
3-Year +1273.08%

Opinion

Sell Hold Buy

Recent Headlines

Axsome Therapeutics Announces AXS-07 Achieves Both

GlobeNewswire via COMTEX - Mon Apr 06, 06:00AM EDT
Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002)(full story)
AXSM: 49.87 (-3.68)

Medical Mushroom Companies Expand as People Seek New

PR Newswire via COMTEX - Tue Mar 31, 08:30AM EDT
The search for ways to improve mental health is driving expansion for a variety of companies looking to offer effective solutions, including treatments that are tapping into the power of psychedelic mushrooms.(full story)
HLF: 29.83 (-0.72), AXSM: 49.87 (-3.68), AGN: 178.26 (+0.11), JNJ: 137.48 (-2.28)

Axsome Therapeutics Announces Topline Results of the

GlobeNewswire via COMTEX - Mon Mar 30, 06:00AM EDT
Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary endpoints, p=0.02, 0.035, and 0.031(full story)
AXSM: 49.87 (-3.68)

Axsome Therapeutics Accelerates Completion of the

GlobeNewswire via COMTEX - Fri Mar 20, 07:00AM EDT
Randomizations concluded and trial participation in process of concluding to ensure patient safety during COVID-19 pandemic(full story)
AXSM: 49.87 (-3.68)

Axsome Therapeutics Reports Fourth Quarter and Full

GlobeNewswire via COMTEX - Thu Mar 12, 07:00AM EDT
NDA filing for Breakthrough Therapy designated AXS-05 in MDD expected in 4Q 2020(full story)
AXSM: 49.87 (-3.68)